Showing results (41-50 of 156) with videos related to

Sort By:
Pageof 16
Clinical Case Reports|January 19, 2017
Response to ibrutinib in chronic lymphocytic leukemia improves in quality with timeStefano Molica, Guido Carillio, Caterina Battaglia
Clinical Case Reports|April 19, 2019
Classic Kaposi's sarcoma with an initial solitary colon lesionGuido Carillio, Luigi Tucci, Stefano Molica
Leukemia & Lymphoma|June 21, 2026
An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysisStefano Molica, Diana Giannarelli, David Allsup
Clinical Lymphoma, Myeloma & Leukemia|June 6, 2025
SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic LeukemiaStefano Molica, Ahmad Ibrahim, David Allsup
Leukemia Research|March 28, 2009
Mast cells and angiogenesis in haematological malignanciesDomenico Ribatti, Enrico Crivellato, Stefano Molica
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2020
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysisStefano Molica, Diana Giannarelli, Emili Montserrat
Clinical Lymphoma, Myeloma & Leukemia|April 28, 2019
Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysisStefano Molica, Diana Giannarelli, Emili Montserrat
Hematological Oncology|October 1, 2021
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agentsStefano Molica, John F Seymour, Aaron Polliack
Hematological Oncology|November 8, 2023
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directionsStefano Molica, Constantine Tam, David Allsup, et al.
Case Reports in Hematology|November 25, 2024
High-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase InhibitionDaniel James, Simone Green, Stefano Molica, et al.
Pageof 16